Valneva Rebounds at Close After IXCHIQ Withdrawal in the US
Valneva's stock closed up 3.93% at 4.386 euros this Thursday, January 22, after experiencing a significant decline earlier in the week. The company announced on Monday evening the voluntary withdrawal of its authorization applications for its chikungunya vaccine IXCHIQ in the United States, following the license suspension by the FDA in August 2025. A new serious adverse event abroad involving a young adult who received three vaccines simultaneously, including IXCHIQ, led the US agency to put the clinical trials on hold. The Nantes-based laboratory indicates it continues to evaluate the global commercial potential of IXCHIQ, focusing on Europe, Latin America, and certain areas of Asia.
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Technically, the stock is trading above its 50-day (3.90 euros) and 200-day (3.55 euros) moving averages, confirming a positive medium-term momentum. The RSI indicator stands at 66, gradually approaching the overbought zone at 70, indicating a resurgence of investor interest after the turbulence at the beginning of the week. However, the price is moving within a range defined by a major support at 3.49 euros and a resistance at 4.43 euros, which was breached at the close this Thursday. Analysts remain divided: the average consensus is to buy with a target price of 6.658 euros, representing a potential increase of 53.77% compared to the last closing price. Stifel recently raised its target from 9.50 to 10 euros while maintaining a buy recommendation, whereas Goldman Sachs lowered its target from 3.50 to 3.25 euros with a neutral recommendation. This divergence reflects the uncertainties surrounding the group's ability to offset the abandonment of the US market for IXCHIQ by developing other vaccine candidates. The one-month volatility reaches 14.43%, reflecting the sensitivity of the case to regulatory and commercial news.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
